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Brain tumor stem cells (BTSC) bear some similarities to neural stem cells (NSC). Bone morphogenetic proteins 
(BMPs) have a proproliferative effect on early embryonic NSC, and a prodifferentiative effect on postnatal 
NSC. In this issue of Cancer Cell, Lee et al. demonstrate that BMPs have differing effects on different BTSC 
lines, either promoting or inhibiting an astrocytic-like differentiation program. This latter effect is the result 
of epigenetic silencing of the BMP receptor 1B (BMPR1B). These findings document the importance of the 
BMP signaling system in BTSC as well as that of taking heterogeneity into account when studying BTSC as 
potential targets for therapy.Glioblastoma multiforme (GBM) is the 
most common brain tumor and one of 
the most highly lethal disorders with a 
median survival of 14.6 months (Stupp 
et al., 2005). The recent discovery of 
neural stem cell-like tumor cells, termed 
“brain tumor stem cells (BTSC),” a kind 
of cancer stem cell, in GBM has created 
a paradigm shift in brain tumor research. 
The BTSC theory dictates that tumors 
arise from a single, self-renewing cell 
type, which then gives rise to the rest of 
the tumor, including a variety of more dif-
ferentiated cell types. Like neural stem 
cells, BTSC have the capacity for self-
renewal and multipotent differentiation 
into cells expressing phenotypic mark-
Figure 1. BMP Effects on Normal Neural 
Stem Cells and Brain Tumor Stem Cells 
BMP effects on normal neural stem cells (top) 
and brain tumor stem cells (tumor initiating cells; 
bottom). In early neural stem cells, BMPs pro-
mote both neuronal differentiation and neural 
stem cell self-renewal. In later neural stem cells, 
the expression of BMPR1B allows the cells to 
respond to BMPs by differentiating into astro-
cytes. This differentiation response is mediated 
by activation of STAT, which can be induced by 
CNTF or LIF. In one type of brain tumor stem 
cell, referred to here as in the article as tumor 
initiating cells (TIC), BMPs promote astrocyte-
like differentiation and inhibit proliferation via 
BMPR1B, which is also dependent on STAT sig-
naling. In another type of TIC (type 2), BMPR1B 
expression is silenced by EZH2, thus preventing 
differentiation and promoting proliferation and 
tumorigenesis.ers of both neurons and glia (Ignatova et 
al., 2002; Hemmati et al., 2003; Singh et 
al., 2003). These cells are competent to 
serve as tumor initiating cells (TIC) in that 
they can form new brain tumors when 
implanted at low densities into immuno-
deficient mouse brain (Galli et al., 2004; 
Singh et al., 2004). The cancer stem 
cell theory, in general and as specifi-
cally applied to brain tumors, dictates 
that any therapy that fails to eradicate 
cancer stem cells can result in recur-
rence or regrowth of the residual tumor 
stem cells, resulting in subsequent fail-
ure of therapy. However, recent studies 
have suggested that BTSC are resistant 
to the currently utilized adjuvant thera-Cancer Cpies for GBM—radiation and temozolo-
mide (Bao et al., 2006; Clement et al., 
2007). Thus, new therapies that target 
BTSC are urgently needed.
One strategy to approach BTSC-
specific therapy is to take advantage of 
current knowledge of neural stem and 
progenitor cell biology. Several stud-
ies have demonstrated numerous simi-
larities between BTSC and the neural 
stem and progenitor cells that have 
been under intense scrutiny for the past 
15 years, due to their potential to con-
tribute to neural repair. Microarray and 
other gene expression analyses sug-
gest that these phenotypic similarities 
are produced through the utilization of ell 13, January 2008 ©2008 Elsevier Inc. 
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Previewsthe same molecular pathways (Hemmati 
et al., 2003; Lee et al., 2006; Phillips et 
al., 2006). Thus, one might propose that 
factors that inhibit proliferation of neural 
stem and progenitor cells will also inhibit 
proliferation of BTSC.
Bone morphogenetic proteins (BMPs) 
are a family of cytokines with a complex 
set of effects on neural stem and pro-
genitor cells. In neural stem cells derived 
from early embryons, BMPs appear to 
promote both proliferation as well as 
neuronal differentiation. In contrast, 
neural stem cells derived from older ani-
mals undergo astrocytic differentiation 
in response to BMPs (Panchision and 
McKay, 2002). This change in response 
patterns is mediated, at least in part in the 
acquisition of new signaling pathways 
by the older stem cells. Early neural 
stem cells express BMPR1A and have a 
limited response to ciliary neurotrophic 
factor (CNTF). On the other hand, older 
stem cells express BMPR1B, which 
then allows them to acquire respon-
siveness to CNTF-induced activation 
of STAT 3, which then promotes astro-
cytic differentiation.
The prodifferentiative role of BMPs 
in neural stem cells prompted investi-
gators to study their roles in putative 
BTSC. Treatment of GBM-derived BTSC 
with BMPs—BMP4 having the strongest 
effect—results in an inhibition of prolif-
eration, induction of differentiation and, 
importantly, a reduction in their abil-
ity to form tumors in immunodeficient 
mice, that is, to serve as TIC (Piccirillo 
et al., 2006). Thus, these TICs behaved 
like “older” neural stem cells in their 
response to BMP. In this issue, Lee and 
colleagues (Lee et al., 2008) also found 
that, in some patient-derived samples, 
BMPs promoted apparent glial differ-
entiation in BTSC (termed TIC in the 
manuscript and in Figure 1). However, in 
one line, BMPs failed to induce glial dif-
ferentiation but, rather, supported prolif-
eration and promoted tumorigenesis. In 
a series of elegant studies, the authors 
found that the reason for these findings 4 Cancer Cell 13, January 2008 ©2008 Elsewas that the BTSC in this line failed to 
express BMPR1B and, thus, did not 
attain competence to respond to CNTF 
or other factors to induce STAT3-depen-
dent glial differentiation. Thus, these 
cells, in some ways, respond like “early” 
neural stem cells. Further studies dem-
onstrate that BMPR1B was epigeneti-
cally silenced by an EZH2-dependent 
mechanism. Further study of multiple 
GBMs demonstrated that a minority, but 
significant number (approximately 20%), 
of GBM tumor samples available to the 
authors had low levels of BMP1RB and 
that the majority of these (6 out of 7) 
had hypermethylation of the promoter, 
demonstrating that the phenomenon 
described for the intensively studied cell 
line is not an isolated one. Of course, 
it will be interesting to determine the 
mechanisms by which those BTSC that 
have normal BMP1RB overcome the ten-
dency to differentiate and maintain their 
self-renewal capacity.
The significance of the study lies not 
only in its elucidation of BMP function 
in BTSC, but also in the demonstration 
of the importance of tumor-to-tumor 
variation in BTSC. Although many stud-
ies have demonstrated commonalities 
among BTSC derived from different 
tumor types and different patients, it is 
clear that there can be fundamental dif-
ferences in phenotypes of BTSC derived 
from different tumors, even when these 
tumors are of equivalent histological 
class and grade. These differences 
among BTSC could reflect both the dif-
ferences between the oncogenic muta-
tions expressed by the cells and their 
progeny and also differences in their 
cells of origin. Many people assume 
that because BTSC have similar proper-
ties to normal NSC, this implicates NSC 
as the cells of origin. However, there are 
multiple progenitor cell types within the 
CNS that have the inherent capacity 
for proliferation and even multilineage 
differentiation, and one might expect 
that the acquisition of oncogenic muta-
tions that enhance their self-renewal vier Inc.capacity would result in differing tumor 
phenotypes. These differences among 
BTSC will ultimately need to be taken 
into account when developing treat-
ments designed to target them for any 
individual patient.
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